CD274 and neoplasm: This is similar to the published outcomes of the first and second line studies, the Checkmate 017 and 057 trials9, 29 (second line nivolumab, received by a majority of our patients), Keynote‐010 trial7, 30 (second line pembrolizumab) and the Keynote‐024 trial5, 31 (first line pembrolizumab for tumours with ≥50% PDL1 expression).